Clinical Trials Browser

INDUSTRY × camrelizumab × Clear all

NCT06361888 2026-05-28

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Phase 2/3 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT03083041 2026-03-03

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Phase 2 Completed

210 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03092895 2026-01-29

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Phase 2 Completed

157 enrolled 17 charts

Gastrointestinal

Advanced Primary Liver Cancer

NCT04342910 2026-01-20

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC

Phase 3 Recruiting

Gastrointestinal

Stomach Neoplasms

NCT04639180 2025-12-30

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Phase 3 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04619433 2025-09-23

A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.

Phase 3 Terminated

Non-squamous Non-small-cell Lung Cancer

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Phase 3 Completed

Gastrointestinal

Stomach Neoplasms

NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

Uterine Cervical Neoplasms, Recurrence

NCT03777124 2025-07-04

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

Carcinoma, Non-Small-Cell Lung

NCT05799183 2024-12-31

A SHR-1210 BE Study on Healthy Subjects

Phase 1 Terminated

Advanced Tumors

NCT03417895 2024-08-07

PASSION

Phase 2 Completed

59 enrolled 17 charts

Small Cell Lung Carcinoma

NCT06335355 2024-03-28

A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients

Phase 2/3 Not yet recruiting

Non-squamous Non-small Cell Lung Cancer

NCT04613674 2024-03-27

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 3 Completed

Triple Negative Breast Neoplasms

NCT03558191 2024-03-15

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Phase 2 Completed

156 enrolled 13 charts

Nasopharyngeal Carcinoma

NCT03711279 2024-02-29

A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma

Phase 2 Terminated

99 enrolled 10 charts

Sarcoma

NCT03764293 2024-02-06

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Phase 3 Completed

543 enrolled 13 charts

Neoplasm Metastasis

NCT03155425 2024-02-01

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

Phase 2 Completed

75 enrolled 10 charts

Hodgkin Disease

NCT03099382 2024-01-22

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Phase 3 Completed

457 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms

NCT03472365 2024-01-11

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Phase 2 Completed

67 enrolled 12 charts

Gastrointestinal

Stomach Neoplasms

NCT05576272 2023-11-22

A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal Carcinoma

Phase 2/3 Unknown

Nasopharyngeal Carcinoma

NCT06124001 2023-11-15

Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma

Phase 1/2 Not yet recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04074564 2023-10-23

MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

Phase EARLY_PHASE1 Unknown

Sarcoma

NCT04346381 2023-09-18

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Phase 2 Completed

Other solid neoplasm

Solid Tumor

NCT05841472 2023-08-30

Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 2 Recruiting

Non Squamous Non Small Cell Lung Cancer

NCT05106335 2023-08-16

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

Phase 3 Terminated

Advanced NSCLC

NCT03871855 2023-06-05

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Advanced Solid Tumor

NCT04335006 2023-05-06

A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer.

Phase 3 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02721589 2023-02-28

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT02742935 2023-02-27

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Phase 1 Completed

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms

NCT03085069 2023-02-16

A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLC

Phase 2 Unknown

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Respiratory Tract Diseases

NCT05214976 2022-12-22

A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients

Phase 2 Unknown

Other solid neoplasm

Advanced Solid Tumors

NCT03691090 2022-12-07

Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Phase 3 Completed

Gastrointestinal

Advanced Esophageal Cancer

NCT05042375 2022-11-17

A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 3 Unknown

Carcinoma, Non-Small-Cell Lung

NCT03182673 2022-09-01

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Phase 1 Terminated

Other solid neoplasm

Solid Tumor

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Phase 1 Completed

Triple Negative Breast Neoplasms

NCT03121716 2022-07-12

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

Phase 1 Completed

Nasopharyngeal Carcinoma

NCT03707509 2022-07-01

Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 3 Unknown

Nasopharyngeal Carcinoma

NCT03827837 2022-07-01

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Phase 2 Unknown

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Endometrial Neoplasms

NCT05429398 2022-06-23

A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor

Phase 1 Unknown

Other solid neoplasm

Advanced Solid Tumor

NCT04426955 2021-09-16

Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer

Phase 3 Unknown

Gastrointestinal

Esophageal Neoplasms

NCT03666728 2021-03-17

A Study of SHR-1210 in Combination With BP102 in Subjects With Non-squamous NSCLC

Phase 2 Terminated

Lung Neoplasms

NCT03668496 2021-03-15

A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC

Phase 3 Unknown

Lung Neoplasms

NCT03363555 2020-06-18

SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma

Phase 2 Unknown

Lymphoma, Extranodal NK-T-Cell

NCT03134872 2020-06-09

A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Phase 3 Completed

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04203485 2020-05-08

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 3 Unknown

PD-L1 Positive Non-small Cell Lung Cancer

NCT02492789 2019-09-30

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

Phase 1 Completed

Other hematologic neoplasm

Hematologic Neoplasms

NCT03393416 2019-08-29

A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild Tumor

Phase 1 Unknown

Gastrointestinal

Advanced Gastric Cancer

NCT03645876 2019-05-10

SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer

Phase 2 Terminated

Gastrointestinal

Colorectal Neoplasms